Abstract
In this study, a series of small molecule inhibitors of human FABP4 were identified through virtual screening. Compound 1 is the most potent hit against FABP4 with a selectivity of more than 144-fold preferences over human FABP3. In addition, MD simulation and mutation studies revealed key residues for inhibitory potency and selectivity, which provides a guideline for further drug design against obesity, diabetes and atherosclerosis.
Copyright 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Atherosclerosis / drug therapy
-
Binding Sites
-
Computer Simulation*
-
Diabetes Mellitus / drug therapy
-
Drug Discovery
-
Drug Evaluation, Preclinical / methods
-
Fatty Acid Binding Protein 3
-
Fatty Acid-Binding Proteins / antagonists & inhibitors*
-
Fatty Acid-Binding Proteins / chemistry
-
Fatty Acid-Binding Proteins / genetics
-
Humans
-
Mutation
-
Obesity / drug therapy
-
Organic Chemicals / chemistry
-
Organic Chemicals / pharmacology
-
Protein Binding / genetics
-
Structure-Activity Relationship
-
Substrate Specificity
Substances
-
FABP3 protein, human
-
FABP4 protein, human
-
Fatty Acid Binding Protein 3
-
Fatty Acid-Binding Proteins
-
Organic Chemicals